Gonasi Set (Human Chorionic Gonadotropin)

Gonasi Set is a prescription medication that contains the hormone human chorionic gonadotropin (hCG) for intramuscular or subcutaneous injection. It is supplied in a sterile injectable form and is marketed in the European Union. The product is classified as a gonadotropin hormone used in fertility and reproductive health management.

Gonasi Set is indicated for several reproductive‑health indications in both women and men.

- Induction of ovulation in assisted reproductive techniques such as in vitro fertilization. - Support of the luteal phase in women with luteal‑phase deficiency. - Stimulation of spermatogenesis in males with hypogonadotropic hypogonadism. - Treatment of undescended testis (cryptorchidism) in pediatric patients. - Adjunct therapy in certain cases of male testosterone deficiency.

Side‑effect profiles for Gonasi Set include both frequently observed reactions and less common but serious events.

Common: - Injection‑site pain or bruising. - Headache. - Fatigue or mild weakness. - Nausea or mild abdominal discomfort. - Mild ovarian swelling in women.

Serious: - Ovarian hyperstimulation syndrome (OHSS) with rapid abdominal distension. - Severe allergic reaction including anaphylaxis. - Thromboembolic events such as deep‑vein thrombosis. - Acute abdominal pain indicating possible ovarian torsion. - Persistent high testosterone levels in men requiring medical review.

Before initiating Gonasi Set, clinicians should evaluate several safety considerations.

- Confirm that the patient is not pregnant before administration. - Assess ovarian response risk to avoid OHSS. - Review thyroid function, as hCG can affect thyroid hormone levels. - Evaluate for known hypersensitivity to hCG or formulation components. - Consider underlying cardiovascular or clotting disorders. - Monitor testosterone levels in male patients during therapy.

Gonasi Set may interact with other medicines, requiring avoidance or careful monitoring.

Avoid: - Estrogen‑containing oral contraceptives, which may reduce hCG efficacy. - GnRH agonists or antagonists that suppress pituitary hormone release. - High‑dose androgenic steroids that can interfere with testosterone response.

Use with caution: - Anticoagulant therapy, because OHSS can increase clot risk. - Thyroid hormone replacement, as hCG may stimulate thyroid activity. - Corticosteroids, which could mask signs of an allergic reaction.